Beta Bionics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	127.27	100.25	65.12	12	0.18
Revenue Growth	43.69%	53.94%	442.93%	6601.12%	-
Cost of Revenue	52.65	44.71	29.24	5.69	-
Gross Profit	74.61	55.54	35.89	6.31	0.18
Selling, General & Admin	124.49	92.43	54.96	24.22	33.5
Research & Development	42.7	34.79	26.18	17.94	31.43
Operating Expenses	167.2	127.22	81.14	42.16	64.92
Operating Income	-92.58	-71.68	-45.25	-35.85	-64.74
Interest Expense	-	-	-	-	-0.01
Interest & Investment Income	9.47	10.93	3.91	1.78	0.2
Other Non Operating Income (Expenses)	-0	-12.45	-13.41	-10.03	0.91
EBT Excluding Unusual Items	-83.12	-73.2	-54.76	-44.1	-63.65
Other Unusual Items	-	-	-	-	-1.1
Pretax Income	-83.12	-73.2	-54.76	-44.1	-64.75
Net Income	-83.12	-73.2	-54.76	-44.1	-64.75
Net Income to Common	-83.12	-73.2	-54.76	-44.1	-64.75
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	45	41	6	5	5
Shares Outstanding (Diluted)	45	41	6	5	5
Shares Change	44.45%	536.74%	20.01%	6.13%	-
EPS (Basic)	-1.85	-1.81	-8.60	-8.31	-12.96
EPS (Diluted)	-1.85	-1.81	-8.60	-8.31	-12.96
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-65.96	-56.22	-51.67	-32.85	-60.98
Free Cash Flow Per Share	-1.47	-1.39	-8.12	-6.19	-12.20
Gross Margin	58.63%	55.40%	55.11%	52.59%	100.00%
Operating Margin	-72.75%	-71.50%	-69.48%	-298.88%	-36169.83%
Profit Margin	-65.31%	-73.02%	-84.08%	-367.64%	-36173.74%
Free Cash Flow Margin	-51.83%	-56.08%	-79.34%	-273.84%	-34067.04%
EBITDA	-89.86	-70.11	-44.1	-34.62	-63.4
EBITDA Margin	-70.61%	-69.93%	-67.72%	-288.65%	-
D&A For EBITDA	2.72	1.57	1.15	1.23	1.35
EBIT	-92.58	-71.68	-45.25	-35.85	-64.74
EBIT Margin	-72.75%	-71.50%	-69.48%	-298.87%	-
Revenue as Reported	-	-	-	-	0.18

SEC Filings: 10-K · 10-Q